Three and a half years into a clinical trial, 86 percent of adults with hypoparathyroidism still met a demanding, multi-component response definition that required normal serum calcium, zero active vitamin D use, and calcium supplementation capped at 600 mg per day. That figure, drawn from Ascendis Pharma’s Week 182 readout of the PaTHway Trial, is striking not just for its magnitude but for what it reveals about durability. Biochemical control in hypoparathyroidism is notoriously difficult to sustain: conventional management with active vitamin D and high-dose calcium suppresses symptoms imperfectly while driving hypercalciuria and progressive renal damage over years. Sustaining this response rate past the four-year horizon, in a disease defined by relentless compensatory calcium dysregulation, reframes what long-term control can actually look like.
The renal signal deserves particular attention. Mean eGFR at Week 182 was 80.2 mL/min/1.73 m², reflecting an average increase of 11.0 mL/min/1.73 m² from baseline. Patients who crossed over from placebo to open-label treatment at Week 26 showed a comparable eGFR improvement, and critically, values held steady from Week 38 onward rather than declining along the typical age-related trajectory. In a population where conventional therapy is a known driver of nephrocalcinosis and renal insufficiency, a durable 11-point eGFR gain is not a soft endpoint. It is the kind of organ-level result that influences prescribing calculus for a chronic, lifelong disease. Bone mineral density Z-scores, which were abnormally elevated at baseline, normalized through Week 26 and remained stable, and 24-hour urine calcium normalized within the same window and stayed there through the trial’s end.
The trial enrolled 82 adults, 85 percent of whom had post-surgical hypoparathyroidism, and 89 percent completed all 182 weeks, an unusually high retention rate for a multi-year open-label extension. No patients developed anti-PTH antibodies, and no discontinuations were attributed to the study drug. Quality-of-life instruments, both the disease-specific HPES and the SF-36, showed rapid and sustained improvement across cognitive, physical, and functional domains. Hypoparathyroidism affects an estimated 37 per 100,000 person-years in the United States, a population that has historically cycled through treatments without meaningful resolution of systemic disease burden.
YORVIPATH received FDA approval in August 2024, and these Week 182 data will now shape the post-approval narrative in a meaningful way: real-world payers and formulary committees making long-term coverage decisions will scrutinize exactly this kind of extended-duration safety and organ-function data. The single number to watch from here is eGFR trajectory in real-world patients, because if the kidney benefit replicates outside the controlled trial setting, it becomes the most defensible argument for prioritizing this therapy over cheaper conventional regimens.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
